FDA authorizes marketing of Medasense’s NOL (nociception level index) technology through a De Novo grant

Agency clearance paves way for commercialization in the United States of first and only authorized device to measure pain in anesthetized patients undergoing surgery

Continue ReadingFDA authorizes marketing of Medasense’s NOL (nociception level index) technology through a De Novo grant